Back

Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures

Darragh, A. C.; Hanna, A. M.; Lipner, J. H.; King, A. J.; Servant, N. B.; Jahic, M.

2024-09-08 pharmacology and toxicology
10.1101/2024.09.06.611550 bioRxiv
Show abstract

AbstractUncovering a drugs mechanism of action and possible adverse effects are critical components in drug discovery and development. Moreover, it provides evidence for why some drugs prove more effective than others, and how to design better drugs altogether. Here we demonstrate the utility of a high- throughput in vitro screening platform along with a comprehensive panel to aid in the characterization of fifteen BTK inhibitors that are either approved by the FDA or presently under clinical evaluation. To compare the potency of these drugs, we measured the binding affinity of each to wild-type BTK, as well as a clinically relevant resistance mutant of BTK (BTK C481S). In doing so, we discovered a considerable difference in the selectivity and potency of these BTK inhibitors to the wild-type and mutant proteins. Some of this potentially contributes to the adverse effects experienced by patients undergoing therapy using these drugs. Overall, non-covalent BTK inhibitors showed stronger potency for both the wild-type and mutant BTK when compared with that of covalent inhibitors, with the majority demonstrating a higher specificity and less off-target modulation. Additionally, we compared biological outcomes for four of these inhibitors in human cell-based models. As expected, we found different phenotypic profiles for each inhibitor. However, the two non-covalent inhibitors had fewer off-target biological effects when compared with the two covalent inhibitors. This and similar in-depth preclinical characterization of drug candidates can provide critical insights into the efficacy and mechanism of action of a compound that may affect its safety in a clinical setting. Table of Contents/Abstract Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=101 SRC="FIGDIR/small/611550v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@744cf2org.highwire.dtl.DTLVardef@167cf2forg.highwire.dtl.DTLVardef@5326c4org.highwire.dtl.DTLVardef@1163b29_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
18.7%
2
Frontiers in Pharmacology
100 papers in training set
Top 0.1%
18.7%
3
PLOS ONE
4510 papers in training set
Top 28%
6.3%
4
Journal of Medicinal Chemistry
68 papers in training set
Top 0.2%
4.9%
5
Scientific Reports
3102 papers in training set
Top 27%
4.3%
50% of probability mass above
6
ChemMedChem
15 papers in training set
Top 0.1%
4.2%
7
SLAS Discovery
25 papers in training set
Top 0.1%
2.7%
8
Pharmacology Research & Perspectives
11 papers in training set
Top 0.1%
2.5%
9
ACS Chemical Biology
150 papers in training set
Top 0.8%
2.1%
10
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.3%
1.9%
11
eLife
5422 papers in training set
Top 38%
1.9%
12
Molecular Pharmaceutics
16 papers in training set
Top 0.3%
1.7%
13
Journal of Chemical Information and Modeling
207 papers in training set
Top 2%
1.7%
14
European Journal of Medicinal Chemistry
16 papers in training set
Top 0.1%
1.3%
15
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.4%
1.3%
16
International Journal of Molecular Sciences
453 papers in training set
Top 11%
1.2%
17
ACS Omega
90 papers in training set
Top 3%
1.1%
18
iScience
1063 papers in training set
Top 23%
1.1%
19
Cancers
200 papers in training set
Top 4%
1.0%
20
PLOS Computational Biology
1633 papers in training set
Top 22%
0.9%
21
Antibody Therapeutics
16 papers in training set
Top 0.4%
0.9%
22
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
23
Cells
232 papers in training set
Top 6%
0.8%
24
Molecules
37 papers in training set
Top 2%
0.7%
25
Molecular Therapy
71 papers in training set
Top 3%
0.7%
26
Viruses
318 papers in training set
Top 6%
0.7%
27
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.6%
0.6%
28
Clinical and Translational Science
21 papers in training set
Top 1%
0.6%